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Some, though, have strongly voiced a repudiation of humanitarian donations in the context of global access to cancer treatment, claiming that it poses a dangerous precedent that may prevent us from saving the lives of hundreds of thousands of patients with cancer. 2 Although long-term sustainable access to high-quality cancer care will only be achieved with a complex, comprehensive, multipronged approach that includes innovative social business models and affordable drugs and other services, the reality is that there are patients today being successfully treated for whom the only path to access is through humanitarian donations of medicines. Unless we define parameters for the role of humanitarian donations and accept them as an important and timely solution, albeit a partial one, thousands of lives will be needlessly lost.
New innovative therapies are not developed for use in low-income countries (LICs), nor are they priced accordingly. Although patients in high-income countries benefit, unless we take drastic measures, many millions of people will suffer premature, preventable death from cancer because of the unavailability and unaffordability of these treatments.
Cancer care infrastructure is weak in many LICs, sometimes lacking the capability to perform critical molecular studies that link targeted therapies with appropriate patients and to safely and effectively administer and monitor these therapies. But there are an ever-increasing number of cancer programs in LICs, often supported by partnerships with cancer centers in the developed world, that can perform the necessary molecular testing and safely and effectively treat and follow these patients. 3 The feasibility of a humanitarian program linked with molecular targeting is demonstrated by the Glivec International Patient Assistance Program (GIPAP), which was the largest and most successful international drug donation program in the history of global oncology. 4 Starting in 2001, the program provided continued access to imatinib to patients with chronic myeloid leukemia (CML) and GI stromal tumor in 80 low-and middle-income countries. More than 75,000 patients benefited from this program managed by The Max Foundation, receiving donated imatinib from Novartis on a continuous basis for as long as their physicians prescribed it. Published patient outcomes have supported the success of this program, which is now being carried forward under the partnership of CMLPath to Care, a joint initiative of Novartis and The Max Foundation. 5 In 2015, the World Health Organization added imatinib and other targeted therapies to their Essential Medicines List for cancer, supporting the potential impact of these drugs. Lessons learned from GIPAP should be considered in today's discussions on humanitarian efforts that can prevent avoidable cancer deaths in LICs. 3. It is often argued that giving free drugs will be ineffective, and even dangerous, if put in the hands of health care providers who lack knowledge, skills, and the needed infrastructure to provide safe and effective care. An essential component of GIPAP and now CMLPath to Care is an assessment of the cancer care delivery infrastructure that must be deemed adequate before a drug is provided.
4. Providing free-of-charge product rather than providing tiered pricing can make business sense for manufacturers, especially when focusing on sophisticated, innovative, and new oncology drugs. On the basis of the economic status of a country and their population, to make a drug affordable, reduction in price for many cancer products would be so high (in many cases > 90%), that it makes more business sense to provide it for free. 7 Furthermore, GIPAP demonstrated that it is possible for a manufacturer to transition to local commercial business after providing humanitarian access for the population of a country. In the case of GIPAP, from the original 80 countries receiving free-of-charge drugs, 40% of the countries currently have commercial programs for imatinib.
Humanitarian access programs are as
important to physicians as they are for patients. Working in greatly challenging environments, being able to treat their patients with these treatments shows that commitment from international bodies translates into more successful and rewarding outcomes and encourages physicians to remain abreast of the latest treatment options.
6. Stigma is a known pervasive factor in leading to premature cancer deaths, but no anti-stigma campaign can succeed in the absence of survivors of cancer. The Max Foundation's model, Max Access Solutions, has resulted in thousands of survivors of cancer in LICs, and survivors are more likely to speak out about their disease, leading to increased awareness and the potential to decrease stigma.
7. Last but not least is the humanitarian side; in this era of globalization, we are leaving our friends behind and they know it. There is only one thing worse than hearing your loved one is diagnosed with cancer: it is to be told that there is a treatment that could help, but because of the place where you live, your loved one cannot access it and will therefore die a premature and avoidable death.
Humanitarian donations of costly life-saving medications are clearly not the answer to all problems arising from the current cancer epidemic, but they can contribute greatly to reducing inequities of care. Widely denouncing the need for donations only gives cover to those who have a responsibility to make their drugs available to these patients in need yet are reluctant to do it. The goal of The Max Foundation's Max
